ECSP099573A - Derivados heterocíclicos como receptores muscarínicos m3 - Google Patents

Derivados heterocíclicos como receptores muscarínicos m3

Info

Publication number
ECSP099573A
ECSP099573A EC2009009573A ECSP099573A ECSP099573A EC SP099573 A ECSP099573 A EC SP099573A EC 2009009573 A EC2009009573 A EC 2009009573A EC SP099573 A ECSP099573 A EC SP099573A EC SP099573 A ECSP099573 A EC SP099573A
Authority
EC
Ecuador
Prior art keywords
muscarinic receptors
heterocyclic derivatives
heterocyclic
derivatives
antagonists
Prior art date
Application number
EC2009009573A
Other languages
English (en)
Inventor
Harry Finch
Nicholas Charles Ray
Alan John Nadin
Barbara Giuseppina Avitabile
Jamie David Knight
Original Assignee
Argenta Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0702994A external-priority patent/GB0702994D0/en
Priority claimed from GB0722678A external-priority patent/GB0722678D0/en
Application filed by Argenta Discovery Ltd filed Critical Argenta Discovery Ltd
Publication of ECSP099573A publication Critical patent/ECSP099573A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta invención se relaciona con antagonistas M3 de la fórmula (I): donde R2, R4, R5, R6, W, V, A, D, X, t, u y v son como se definió aquí; las composiciones farmacéuticas que los contienen los métodos para su preparación; y su uso en el tratamiento de enfermedades donde la activación del receptor M3 reforzada está implicada.
EC2009009573A 2007-02-15 2009-08-12 Derivados heterocíclicos como receptores muscarínicos m3 ECSP099573A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0702994A GB0702994D0 (en) 2007-02-15 2007-02-15 Compound and thier use
GB0722678A GB0722678D0 (en) 2007-11-19 2007-11-19 Compounds and their use II

Publications (1)

Publication Number Publication Date
ECSP099573A true ECSP099573A (es) 2009-12-28

Family

ID=39323641

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009573A ECSP099573A (es) 2007-02-15 2009-08-12 Derivados heterocíclicos como receptores muscarínicos m3

Country Status (21)

Country Link
US (1) US20100056565A1 (es)
EP (1) EP2121688A1 (es)
JP (1) JP2010519193A (es)
KR (1) KR20090110353A (es)
CN (1) CN101657452A (es)
AR (1) AR065344A1 (es)
AU (1) AU2008215924B2 (es)
BR (1) BRPI0807913A2 (es)
CA (1) CA2676581A1 (es)
CL (1) CL2008000474A1 (es)
CO (1) CO6190612A2 (es)
EC (1) ECSP099573A (es)
IL (1) IL199971A0 (es)
MX (1) MX2009008323A (es)
NZ (1) NZ578489A (es)
PE (1) PE20090357A1 (es)
RU (1) RU2009133258A (es)
SA (1) SA08290066B1 (es)
TW (1) TW200843759A (es)
UY (1) UY30916A1 (es)
WO (1) WO2008099186A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2009098453A1 (en) * 2008-02-06 2009-08-13 Astrazeneca Ab Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists
WO2009138707A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
WO2010018352A1 (en) * 2008-08-12 2010-02-18 Argenta Discovery Limited Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated
GB0814728D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
BRPI0917978A2 (pt) * 2008-08-12 2015-11-17 Astrazeneca Ab sal de 2-hidróxi-etanossulfonato
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
CN104418851A (zh) * 2013-09-02 2015-03-18 上海龙翔生物医药开发有限公司 奎宁环衍生物的制备方法及纯化方法
CN106573928B (zh) * 2014-08-26 2020-04-14 安斯泰来制药株式会社 2-氨基噻唑衍生物或其盐

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
IL88846A0 (en) * 1988-01-08 1989-07-31 Merck Sharp & Dohme Lipophilic oxadiazoles,their preparation and pharmaceutical compositions containing them
GB9603755D0 (en) * 1996-02-22 1996-04-24 Pfizer Ltd Therapeutic agents
DE19856475A1 (de) * 1998-11-27 2000-05-31 Schering Ag Nichtsteroidale Entzündungshemmer
US20020052312A1 (en) * 2000-05-30 2002-05-02 Reiss Theodore F. Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists
WO2002053564A2 (en) * 2000-12-28 2002-07-11 Almirall Prodesfarma Ag Quinuclidine derivatives and their use as m3 antagonists
DE60326894D1 (de) * 2002-09-30 2009-05-07 Neurosearch As 1,4-Diazabicycloalkanderivate, deren Herstellung und Verwendung
MXPA05003344A (es) * 2002-09-30 2005-11-23 Neurosearch As Derivados novedosos de 1,4-diazabicicloalcano, su preparacion y uso.
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
GB0516313D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses

Also Published As

Publication number Publication date
AU2008215924B2 (en) 2011-04-21
WO2008099186A1 (en) 2008-08-21
CL2008000474A1 (es) 2008-08-22
JP2010519193A (ja) 2010-06-03
RU2009133258A (ru) 2011-03-20
MX2009008323A (es) 2009-08-13
AR065344A1 (es) 2009-06-03
SA08290066B1 (ar) 2011-05-14
BRPI0807913A2 (pt) 2014-06-17
EP2121688A1 (en) 2009-11-25
KR20090110353A (ko) 2009-10-21
PE20090357A1 (es) 2009-04-01
AU2008215924A1 (en) 2008-08-21
CN101657452A (zh) 2010-02-24
US20100056565A1 (en) 2010-03-04
CO6190612A2 (es) 2010-08-19
NZ578489A (en) 2011-05-27
IL199971A0 (en) 2010-04-15
UY30916A1 (es) 2008-09-30
WO2008099186A8 (en) 2008-11-13
CA2676581A1 (en) 2008-08-21
TW200843759A (en) 2008-11-16

Similar Documents

Publication Publication Date Title
ECSP099573A (es) Derivados heterocíclicos como receptores muscarínicos m3
UY31124A1 (es) Derivados de oxiadazol y su uso como potenciadores del receptor metabotropico de glutamato - 842
ECSP066856A (es) Compuestos novedosos como moduladores del receptor opioide
CR10236A (es) Modulares del indol sulfonamida de receptores de progesterona
CR10545A (es) Prolinamida-2-5-oxo fenilmetil-n-sustituidos como receptores antagonistas y sus metodos de uso
UY29267A1 (es) Derivados de piperidina y su uso como agentes antiinflamatorios
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
SV2006002098A (es) Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central ref. pc32250a
ECSP099394A (es) Derivados de quinuclidinol como antogonistas de receptores muscarínicos
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
ECSP099370A (es) Derivados de hidantoína usados como inhibidores de mmp
CR10243A (es) "bencimidazoles 2-sustituidos como modulares de receptor de androgeno selectivos"
HN2010001563A (es) Compuestos
CL2011000917A1 (es) Compuestos derivados de tioamida; sus metodos de preparacion y uso de los compuestos para el tratamiento de enfermedades endoparasitarias.
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
ECSP067121A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
NI201000090A (es) Agonistas novedosos de los receptores de glucocorticoides.
ECSP088265A (es) Derivados de carboxamida como antagonistas del receptor muscarínico
CR10489A (es) Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides
AR060536A1 (es) Agonista del receptor de glucocorticoides y composiciones farmaceuticas
MX2020014156A (es) Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4.
CO6420342A2 (es) Derivados de pirazol usados como antagonistas del receptor ccr4
UY30534A1 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapéutica como antagonistas de los receptores de urotensina ii
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
CO6300937A2 (es) Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu